Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Change in Accured Expenses (2016 - 2025)

Coherus Oncology's Change in Accured Expenses history spans 13 years, with the latest figure at -$4.2 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 108.08% year-over-year to -$4.2 million; the TTM value through Dec 2025 reached -$9.2 million, down 693.87%, while the annual FY2025 figure was -$9.2 million, 693.87% down from the prior year.
  • Change in Accured Expenses for Q4 2025 was -$4.2 million at Coherus Oncology, down from $10.0 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $52.5 million in Q4 2024 and bottomed at -$48.3 million in Q3 2024.
  • The 5-year median for Change in Accured Expenses is -$1.2 million (2022), against an average of $1.1 million.
  • The largest annual shift saw Change in Accured Expenses surged 1320.75% in 2024 before it crashed 634.0% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at $21.4 million in 2021, then plummeted by 248.35% to -$31.7 million in 2022, then skyrocketed by 111.64% to $3.7 million in 2023, then soared by 1320.75% to $52.5 million in 2024, then plummeted by 108.08% to -$4.2 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Change in Accured Expenses are -$4.2 million (Q4 2025), $10.0 million (Q3 2025), and -$6.6 million (Q2 2025).